SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

High diagnostic rate of trio exome sequencing in consanguineous families with neurogenetic diseases.

Hiz Kurul, S; Oktay, Y; Töpf, A; Szabó, NZ; Güngör, S; Yaramis, A; Sonmezler, E; Matalonga, L; Yis, U; Schon, K; et al. Hiz Kurul, S; Oktay, Y; Töpf, A; Szabó, NZ; Güngör, S; Yaramis, A; Sonmezler, E; Matalonga, L; Yis, U; Schon, K; Paramonov, I; Kalafatcilar, İP; Gao, F; Rieger, A; Arslan, N; Yilmaz, E; Ekinci, B; Edem, PP; Aslan, M; Özgör, B; Lochmüller, A; Nair, A; O'Heir, E; Lovgren, AK; Broad Center for Mendelian Genomics; Maroofian, R; Houlden, H; Polavarapu, K; Roos, A; Müller, JS; Hathazi, D; Chinnery, PF; Laurie, S; Beltran, S; Lochmüller, H; Horvath, R (2022) High diagnostic rate of trio exome sequencing in consanguineous families with neurogenetic diseases. Brain, 145 (4). pp. 1507-1518. ISSN 1460-2156 https://doi.org/10.1093/brain/awab395
SGUL Authors: Maroofian, Reza

[img] PDF Published Version
Available under License Creative Commons Attribution.

Download (1MB)
[img] Archive (ZIP) (Supplementary data) Published Version
Available under License Creative Commons Attribution.

Download (678kB)

Abstract

Consanguineous marriages have a prevalence rate of 24% in Turkey. These carry an increased risk of autosomal recessive genetic conditions, leading to severe disability or premature death, with a significant health and economic burden. A definitive molecular diagnosis could not be achieved in these children previously, as infrastructures and access to sophisticated diagnostic options were limited. We studied the cause of neurogenetic disease in 246 children from 190 consanguineous families recruited in three Turkish hospitals between 2016 and 2020. All patients underwent deep phenotyping and trio whole exome sequencing, and data were integrated in advanced international bioinformatics platforms. We detected causative variants in 119 known disease genes in 72% of families. Due to overlapping phenotypes 52% of the confirmed genetic diagnoses would have been missed on targeted diagnostic gene panels. Likely pathogenic variants in 27 novel genes in 14% of the families increased the diagnostic yield to 86%. Eighty-two per cent of causative variants (141/172) were homozygous, 11 of which were detected in genes previously only associated with autosomal dominant inheritance. Eight families carried two pathogenic variants in different disease genes. De novo (9.3%), X-linked recessive (5.2%) and compound heterozygous (3.5%) variants were less frequent compared to non-consanguineous populations. This cohort provided a unique opportunity to better understand the genetic characteristics of neurogenetic diseases in a consanguineous population. Contrary to what may be expected, causative variants were often not on the longest run of homozygosity and the diagnostic yield was lower in families with the highest degree of consanguinity, due to the high number of homozygous variants in these patients. Pathway analysis highlighted that protein synthesis/degradation defects and metabolic diseases are the most common pathways underlying paediatric neurogenetic disease. In our cohort 164 families (86%) received a diagnosis, enabling prevention of transmission and targeted treatments in 24 patients (10%). We generated an important body of genomic data with lasting impacts on the health and wellbeing of consanguineous families and economic benefit for the healthcare system in Turkey and elsewhere. We demonstrate that an untargeted next generation sequencing approach is far superior to a more targeted gene panel approach, and can be performed without specialized bioinformatics knowledge by clinicians using established pipelines in populations with high rates of consanguinity.

Item Type: Article
Additional Information: © The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Keywords: consanguineous families, neurogenetic disease burden, rate of consanguinity, whole exome sequencing, Consanguinity, Exome, Homozygote, Humans, Mutation, Pedigree, Phenotype, Whole Exome Sequencing, Broad Center for Mendelian Genomics, Humans, Pedigree, Consanguinity, Homozygote, Phenotype, Mutation, Exome, Whole Exome Sequencing, consanguineous families, neurogenetic disease burden, whole exome sequencing, rate of consanguinity, 11 Medical and Health Sciences, 17 Psychology and Cognitive Sciences, Neurology & Neurosurgery
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Journal or Publication Title: Brain
ISSN: 1460-2156
Language: eng
Dates:
DateEvent
24 May 2022Published
17 November 2021Published Online
26 September 2021Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
UM1 HG008900NHGRI NIH HHSUNSPECIFIED
MR/N025431/1Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
MR/N010035/1Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
G1000848Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
MR/N025431/2Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
R01 HG009141NHGRI NIH HHSUNSPECIFIED
309548European Research Councilhttp://dx.doi.org/10.13039/501100000781
201064/Z/16/ZWellcome Trusthttp://dx.doi.org/10.13039/100004440
MR/V009346/1Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
216S771Scientific and Technological Research Council of TurkeyUNSPECIFIED
212219/Z/18/ZWellcome Trusthttp://dx.doi.org/10.13039/100004440
MC_UU_00015/9Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
RPG-2018–408Leverhulme Trusthttp://dx.doi.org/10.13039/501100000275
MR/S035699/1Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
AS-PG-18b-022Alzheimer's SocietyUNSPECIFIED
BRC-1215–20014National Institute for Health Researchhttp://dx.doi.org/10.13039/501100000272
309548European Research Councilhttp://dx.doi.org/10.13039/501100000781
109915/Z/15/ZWellcome Trusthttp://dx.doi.org/10.13039/100004440
MR/N027302/1Newton FundUNSPECIFIED
G100142Addenbrooke's Charitable Trust, Cambridge University Hospitalshttp://dx.doi.org/10.13039/501100002927
FDN-167281Canadian Institutes of Health Researchhttp://dx.doi.org/10.13039/501100000024
NMD4CMuscular Dystrophy Canadahttp://dx.doi.org/10.13039/501100000223
CFI-JELF 38412Canada Foundation for Innovationhttp://dx.doi.org/10.13039/501100000196
950–232279Canada Research Chairshttp://dx.doi.org/10.13039/501100001804
305444Seventh Framework Programmehttp://dx.doi.org/10.13039/501100004963
779257Horizon 2020UNSPECIFIED
MR/S005021/1Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
PubMed ID: 34791078
Web of Science ID: WOS:000784790600001
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/114579
Publisher's version: https://doi.org/10.1093/brain/awab395

Actions (login required)

Edit Item Edit Item